News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging transposon-based gene delivery to compress timelines, increase clone stability, and offer uncompromising titers. As an integral enabler of our innovative Portable CMC™ Clone Selection service, this cutting-edge approach is a key differentiator to our CLD services.
As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply risk-based thinking to manufacturing innovation.
The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.
For more product information visit Wheeler Bio.